A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Background: A phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral or intravenous vinorelbine (VRL) plus cisplatin (CDDP) in Chinese patients with non-small cell lung cancer (NSCLC).

Methods: One hundred and thirty-one patients were randomised to oral VRL 60 mg/m (arm A) or intravenous VRL 25 mg/m (arm B) on days 1 and 8, plus CDDP 80 mg/m on day 1 (both arms). VRL was increased to 80 mg/m (arm A) or 30 mg/m (arm B) in cycles 2-4 in the absence of toxicity.

Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.

Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma.

Patients And Methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m2 on d 1 and d 8 and cisplatin 100 mg/m2 on day 1 every 4 weeks.

Results: Thirty-seven patients were evaluable for response and 40 patients for tolerance.